SEARCH

SEARCH BY CITATION

References

  • 1
    Ohaeri JU, Akanji AO. Metabolic syndrome in severe mental disorders. Metab Syndr Relat Disord 2011;9:9198.
  • 2
    van Winkel R, van Os J, Celic I et al. Psychiatric diagnosis as an independent risk factor for metabolic disturbances: results from a comprehensive, naturalistic screening program. J Clin Psychiatry 2008;69:13191327.
  • 3
    Young AH, Grunze H. Physical health of patients with bipolar disorder. Acta Psychiatr Scand 2013;127:310.
  • 4
    Von Hausswolff-Juhlin Y, Bjartveit M, Lindström E, Jones P. Schizophrenia and physical health problems. Acta Psychiatr Scand 2009;119:1521.
  • 5
    McIntyre RS, Rasgon NL, Kemp DE et al. Metabolic syndrome and major depressive disorder: co-occurrence and pathophysiologic overlap. Curr Diab Rep 2009;9:5159.
  • 6
    McIntyre RS, Danilewitz M, Liauw SS et al. Bipolar disorder and metabolic syndrome: an international perspective. J Affect Disord 2010;126:366387.
  • 7
    Mitchell AJ, Vancampfort D, Sweers K, van Winkel R, Yu W, de Hert M. Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders- a systematic review and meta-analysis. Schizophr Bull 2013;39:306318.
  • 8
    Magalhães PV, Kapczinski F, Nierenberg AA et al. Illness burden and medical comorbidity in the Systematic Treatment Enhancement Program for Bipolar Disorder. Acta Psychiatr Scand 2012;125:303308.
  • 9
    Kahl KG, Greggersen W, Schweiger U et al. Prevalence of the metabolic syndrome in unipolar major depression. Eur Arch Psychiatry Clin Neurosci 2012;262:313320.
  • 10
    Goldbacher EM, Bromberger J, Matthews KA. Lifetime history of major depression predicts the development of the metabolic syndrome in middle-aged women. Psychosom Med 2009;71:266272.
  • 11
    Guo JJ, Keck PE, Li H, Patel NC. Treatment costs related to bipolar disorder and comorbid conditions among Medicaid patients with bipolar disorder. Psychiatr Serv 2007;58:10731078.
  • 12
    Oda E. Metabolic syndrome: its history, mechanisms, and limitations. Acta Diabetol 2012;49:8995.
  • 13
    Roberts CK, Sindhu KK. Oxidative stress and metabolic syndrome. Life Sci 2009;84:705712.
  • 14
    Fisman EZ, Tenenbaum A. The metabolic syndrome entanglement: cutting the Gordian knot. Cardiol J 2014;21:15.
  • 15
    Adibatla RM, Hatcher JF. Lipid oxidation and peroxidation in CNS health and disease: from molecular mechanisms to therapeutic opportunities. Antioxid Redox Signal 2010;12:125169.
  • 16
    Schiavone S, Jacquet V, Trabace L, Krause KH. Severe life stress and oxidative stress in the brain: from animal models to human pathology. Antioxid Redox Signal 2012;18:14751490.
  • 17
    Wallace DC. Colloquium paper: bioenergetics, the origins of complexity, and the ascent of man. Proc Natl Acad Sci USA 2010;107(Suppl 2):89478953.
  • 18
    Giustarini D, Dalle-Donne I, Tsikas D, Rossi R. Oxidative stress and human diseases: origin, link, measurement, mechanisms, and biomarkers. Crit Rev Clin Lab Sci 2009;46:241281.
  • 19
    Voss P, Siems W. Clinical oxidation parameters of aging. Free Radic Res 2006;40:13391349.
  • 20
    Niki E. Assessment of antioxidant capacity in vitro and in vivo. Free Radic Biol Med 2010;49:503515.
  • 21
    Gomes EC, Silva AN, de Oliveira MR. Oxidants, antioxidants, and the beneficial roles of exercise-induced production of reactive species. Oxid Med Cell Longev 2012;2012:756132.
  • 22
    Yan Z, Lira VA, Greene NP. Exercise training-induced regulation of mitochondrial quality. Exerc Sport Sci Rev 2012;40:159164.
  • 23
    Ristow M, Zarse K, Oberbach A et al. Antioxidants prevent health-promoting effects of physical exercise in humans. Proc Natl Acad Sci USA 2009;106:86658670.
  • 24
    Manji H, Kato T, di Prospero NA et al. Impaired mitochondrial function in psychiatric disorders. Nat Rev Neurosci 2012;13:293307.
  • 25
    Sugamura K, Keaney JF. Reactive oxygen species in cardiovascular disease. Free Radic Biol Med 2011;51:978992.
  • 26
    Flores-Mateo G, Carrillo-Santisteve P, Elosua R et al. Antioxidant enzyme activity and coronary heart disease: meta-analyses of observational studies. Am J Epidemiol 2009;170:135147.
  • 27
    Ceriello A, Motz E. Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited. Arterioscler Thromb Vasc Biol 2004;24:816823.
  • 28
    Urakawa H, Katsuki A, Sumida Y et al. Oxidative stress is associated with adiposity and insulin resistance in men. J Clin Endocrinol Metab 2003;88:46734676.
  • 29
    Houstis N, Rosen ED, Lander ES. Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature 2006;440:944948.
  • 30
    Anderson EJ, Lustig ME, Boyle KE et al. Mitochondrial H2O2 emission and cellular redox state link excess fat intake to insulin resistance in both rodents and humans. J Clin Invest 2009;119:573581.
  • 31
    Ng F, Berk M, Dean O, Bush AI. Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. Int J Neuropsychopharmacol 2008;11:851876.
  • 32
    Can M, Guven B, Atik L, Konuk N. Lipid peroxidation and serum antioxidant activity in patients with bipolar and major depressive disorders. Journal of Mood Disorders 2011;1:1418.
  • 33
    Kunz MC, Gama CS, Andreazza AC et al. Elevated serum superoxide dismutase and thiobarbituric acid reactive substances in different phases of bipolar disorder and in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:16771681.
  • 34
    Maes M, Mihaylova I, Kubera M, Uytterhoeven M, Vrydags N, Bosmans E. Increased plasma peroxides and serum oxidized low density lipoprotein antibodies in major depression: markers that further explain the higher incidence of neurodegeneration and coronary artery disease. J Affect Disord 2010;125:287294.
  • 35
    Stefanescu C, Ciobica A. The relevance of oxidative stress status in first episode and recurrent depression. J Affect Disord 2012;143:3438.
  • 36
    Versace A, Andreazza AC, Young LT et al. Elevated serum measures of lipid peroxidation and abnormal prefrontal white matter in euthymic bipolar adults: toward peripheral biomarkers of bipolar disorder. Mol Psychiatry 2014;19:20002008.
  • 37
    Flatow J, Buckley P, Miller BJ. Meta-analysis of oxidative stress in schizophrenia. Biol Psychiatry 2013;74:400409.
  • 38
    Ben-Sachar D, Karry R. Neuroanatomical pattern of mitochondrial complex I pathology varies between schizophrenia, bipolar disorder and major depression. PLoS ONE 2008;3:e3676.
  • 39
    Gardner A, Boles RG. Beyond the serotonin hypothesis: mitochondria, inflammation and neurodegeneration in major depression and affective spectrum disorders. Prog Neuropsychopharmacol Biol Psychiatry 2011;35:730743.
  • 40
    van Meer G, Voelker DR, Feigenson GW. Membrane lipids: where they are and how they behave. Nat Rev Mol Cell Biol 2008;9:112124.
  • 41
    Flowers MT, Ntambi JM. Role of stearoyl-coenzyme A desaturase in regulating lipid metabolism. Curr Opin Lipidol 2008;19:248256.
  • 42
    Jacobsson A, Westerberg R. Fatty acid elongases in 14 mammals: their regulation and roles in metabolism. Prog Lipid Res 2006;45:215249.
  • 43
    Nakamura MT, Nara TY. Structure, function, and dietary regulation of delta6, delta5, and delta9 desaturases. Annu Rev Nutr 2004;24:345376.
  • 44
    Hodson L, Skeaff CM, Fielding BA. Fatty acid composition of adipose tissue and blood in humans and its use as a biomarker of dietary intake. Prog Lipid Res 2008;47:348380.
  • 45
    Escriba PV, Gonzales-Ros JM, Goni FM et al. Membranes: a meeting point for lipids, proteins and therapies. J Cell Mol Med 2008;12:829875.
  • 46
    McNamara RK, Carlson SE. Role of omega-3 fatty acids in brain development and function: potential implications for the pathogenesis and prevention of psychopathology. Prostaglandins Leukot Essent Fatty Acids 2006;75:329349.
  • 47
    Breslow DK, Weissman JS. Membranes in balance: mechanisms of sphingolipid homeostasis. Mol Cell 2010;40:267279.
  • 48
    Delarue J, Matzinger O, Binnert C, Schneiter P, Chiolero R, Tappy L. Fish oil prevents the adrenal activation elicited by mental stress in healthy men. Diabetes Metab 2003;29:289295.
  • 49
    Hamazaki K, Itomura M, Huan M et al. Effect of omega-3 fatty acid-containing phospholipids on blood catecholamine concentrations in healthy volunteers: a randomized, placebo-controlled, double-blind trial. Nutrition 2005;21:705710.
  • 50
    Lafourcade M, Larrieu T, Mato S et al. Nutritional omega-3 deficiency abolishes endocannabinoid-mediated neuronal functions. Nat Neurosci 2011;14:345350.
  • 51
    Meijerink J, Balvers M, Witkamp R. N-acyl amines of docosahexaenoic acid and other n-3 polyunsatured fatty acids – From fishy endocannabinoids to potential leads. Br J Pharmacol 2013;169:772783.
  • 52
    Mocking RJT, Ruhe HG, Assies J et al. Relationship between the hypothalamic-pituitary-adrenal-axis and fatty acid metabolism in recurrent depression. Psychoneuroendocrinology 2013;38:16071617.
  • 53
    Rao JS, Ertley RN, Lee HJ et al. N-3 polyunsaturated fatty acids deprivation in rats decreases frontal cortex BDNF via a p38 MAPK-dependent mechanism. Mol Psychiatry 2006;12:3646.
  • 54
    Beltz BS, Tlusty MF, Benton JL, Sandeman DC. Omega-3 fatty acids upregulate adult neurogenesis. Neurosci Lett 2007;415:154158.
  • 55
    Calderon F, Kim HY. Docosahexaenoic acid promotes neurite growth in hippocampal neurons. J Neurochem 2004;90:979988.
  • 56
    Kawakita E, Hashimoto M, Shido O. Docosahexaenoic acid promotes neurogenesis in vitro and in vivo. Neuroscience 2006;139:991997.
  • 57
    Mozaffarian D, Wu JHY. Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events. J Am Coll Cardiol 2011;58:20472067.
  • 58
    Quehenberger O, Armando AM, Brown AH et al. Lipidomics reveals a remarkable diversity of lipids in human plasma. J Lipid Res 2010;51:32993305.
  • 59
    Hulbert AJ, Pamplona R, Buffenstein R, Buttemer WA. Life and death: metabolic rate, membrane composition, and life span of animals. Physiol Rev 2007;87:11751213.
  • 60
    Catala A. Lipid peroxidation of membrane phospholipids generates hydroxyl-alkenals and oxidized phospholipids in physiological and/or pathological conditions. Chem Phys Lipids 2009;157:111.
  • 61
    Niki E. Lipid peroxidation: physiological levels and dual biological effects. Free Radic Biol Med 2009;47:469484.
  • 62
    Schonfeld P, Wojtczak L. Fatty acids as modulators of the cellular production of reactive oxygen species. Free Radic Biol Med 2008;45:231241.
  • 63
    Warensjo E, Riserus U, Vessby B. Fatty acid composition of serum lipids predicts the development of the metabolic syndrome in men. Am J Clin Nutr 2006;84:442444.
  • 64
    Skidmore PML, Woodside JV, Mc Master C et al. Plasma free fatty acid patterns and their relationship with CVD risk in a male middle-aged population. Eur J Clin Nutr 2010;64:239244.
  • 65
    Kröger J, Zieteman V, Enzenbach C et al. Erythrocyte membrane fatty acids, desaturase activity, and dietary fatty acids in relation to risk of type 2 diabetes in the European Prospective Investigation into Cancer (EPIC)-Potsdam study. Am J Clin Nutr 2011;93:127142.
  • 66
    Khaw KT, Friesen MD, Riboli E, Luben R, Wareham N. Plasma phospholipid fatty acid concentration and incident coronary heart disease in men and women: the EPIC-Norfolk prospective study. PLoS ONE 2012;9:e1001255.
  • 67
    Enzenbach C, Kroger J, Zietemann V et al. Erythrocyte membrane phospholipid polyunsaturated fatty acids are related to plasma C-reactive protein and adiponectin in middle-aged German women and men. Eur J Nutr 2011;50:625636.
  • 68
    Zak A, Turzicka E, Vecka M et al. Duffkova, and Severity of metabolic syndrome unfavourably influences oxidative stress and fatty acid metabolism in men. Tohoku J Exp Med 2007;212:359371.
  • 69
    Huang T, Bhulaidok S, Cai Z et al. Plasma phospholipids n-3 polyunsaturated fatty acid is associated with metabolic syndrome. Mol Nutr Food Res 2010;54:16281635.
  • 70
    Sethom MM, Fares S, Feki M et al. Plasma fatty acids profile and estimated elongase and desaturases activities in Tunisian patients with the metabolic syndrome. Prostaglandins Leukot Essent Fatty Acids 2011;85:137141.
  • 71
    Meigs JB, Larson MG, Fox CS, Keaney JF, Vasan RS, Benjamin EJ. Association of oxidative stress, insulin resistance, and diabetes risk phenotypes: the Framingham Offspring Study. Diabetes Care 2007;30:25292535.
  • 72
    Fujita K, Nishizawa H, Funahashi T, Shimomura I, Shimabukuro M. Systemic oxidative stress is associated with visceral fat accumulation and the metabolic syndrome. Circ J 2006;70:14371442.
  • 73
    Lin PY, Huang SY, Su KP. A meta-analytic review of polyunsaturated fatty acid compositions in patients with depression. Biol Psychiatry 2010;68:140147.
  • 74
    McNamara RK, Jandacek R, Rider T, Tso P, Dwivedi Y, Pandey GN. Selective deficits in erythrocyte docosahexaenoic acid composition in adult patients with bipolar disorder and major depressive disorder. J Affect Disord 2010;126:303311.
  • 75
    Assies J, Pouwer F, Lok A et al. Plasma and erythrocyte fatty acid patterns in patients with recurrent depression: a matched case-control study. PLoS ONE 2010;5:e10635.
  • 76
    Astorg P, Bertrais S, Alessandri JM et al. Long-chain n-3 fatty acid levels in baseline serum phospholipids do not predict later occurrence of depressive episodes: a nested case-control study within a cohort of middle-aged French men and women. Prostaglandins Leukot Essent Fatty Acids 2009;81:265271.
  • 77
    Vareka T, Vecka M, Jirak R et al. Plasma fatty acid profile in depressive disorder resembles insulin resistance state. Neuro Endocrinol Lett 2012;33(Suppl 2):8386.
  • 78
    Hoen WP, Lijmer JG, Duran M, Wanders RJA, van Beveren NJM, de Haan L. Red blood cell polyunsaturated fatty acids measured in red blood cells and schizophrenia: a meta-analysis. Psychiatry Res 2013;207:112.
  • 79
    Bitanirhirwe BKY, Woo TU. Oxidative stress in schizophrenia: an integrated approach. Neurosci Biobehav Rev 2011;35:878893.
  • 80
    Yao JK, Keshavan MS. Antioxidants, redox signaling, and pathophysiology in schizophrenia: an integrative view. Antioxid Redox Signal 2011;15:20112035.
  • 81
    Ben Othmen L, Mechri A, Fendri C et al. Altered antioxidant defense system in clinically stable patients with schizophrenia and their unaffected siblings. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:155159.
  • 82
    Khan MM, Evans DR, Gunna V, Scheffer RE, Parikh VV, Mahadik SP. Reduced erythrocyte membrane essential fatty acids and increased lipid peroxides in schizophrenia at the never-medicated first-episode of psychosis and after years of treatment with antipsychotics. Schizophr Res 2002;58:110.
  • 83
    Stanger O, Fowler B, Piertzik K et al. Homocysteine, folate and vitamin B12 in neuropsychiatric diseases: review and treatment recommendations. Expert Rev Neurother 2009;9:13931412.
  • 84
    Forman HJ, Zhang H, Rinna A. Glutathione: overview of its protective roles, measurement, and biosynthesis. Mol Aspects Med 2009;30:112.
  • 85
    McGowan PO, Meany MJ, Szyf M. Diet and the epigenetic (re)programming of phenotypic differences in behaviour. Brain Res 2008;1237:1224.
  • 86
    Widner B, Enzinger C, Laich A, Wirleitner B, Fuchs D. Hyperhomocysteinemia, pteridines and oxidative stress. Curr Drug Metab 2002;3:225232.
  • 87
    Hoffman M. Hypothesis: hyperhomocysteinemia is an indicator of oxidant stress. Med Hypotheses 2011;77:10881093.
  • 88
    Obeid R, Herrmann W. Homocysteine and lipids: S-adenosyl methionine as a key intermediate. FEBS Lett 2009;583:12151225.
  • 89
    Selley ML. A metabolic link between S-adenosylhomocysteine and polyunsaturated fatty acid metabolism in Alzheimer's disease. Neurobiol Aging 2007;28:18341839.
  • 90
    Humphrey LL, Fu R, Rogers K, Freeman M, Helfand M. Homocysteine level and coronary heart disease incidence: a systematic review and meta-analysis. Mayo Clin Proc 2008;83:12031212.
  • 91
    Wang ZM, Zhou B, Nie ZL et al. Folate and risk of coronary heart disease: a meta-analysis of prospective studies. Nutr Metab Cardiovasc Dis 2012;22:890899.
  • 92
    Bjorck J, Hellgren M, Rastam L, Lindblad U. Associations between serum insulin and homocysteine in a Swedish population-a potential link between the metabolic syndrome and hyperhomocysteinemia: the Skaraborg project. Metabolism 2006;55:10071013.
  • 93
    Folstein M, Liu T, Peter I et al. The homocysteine hypothesis of depression. Am J Psychiatry 2007;164:861867.
  • 94
    Krebs MO, Bellon A, Mainguy G, Jay TM, Frieling H. One-carbon metabolism and schizophrenia: current challenges and future directions. Trends Mol Med 2009;15:562570.
  • 95
    Sugden C. One-carbon metabolism in psychiatric illness. Nutr Res Rev 2006;19:117136.
  • 96
    Gu P, Defina LF, Leonard D, John S, Weiner MF, Brown ES. Relationship between serum homocysteine levels and depressive symptoms: the Cooper Center Longitudinal Study. J Clin Psychiatry 2012;73:691695.
  • 97
    Kale A, Naphade N, Sapkale S et al. Reduced folic acid, vitamin B12 and docosahexaenoic acid and cortisol in never-medicated schizophrenic patients: implications for altered one-carbon-metabolism. Psychiatry Res 2010;175:4753.
  • 98
    Li D, Mann NJ, Sinclair AJ. A significant inverse relationship between concentrations of plasma homocysteine and phospholipid docosahexaenoic acid in healthy male subjects. Lipids 2006;41:8589.
  • 99
    Severus WE, Littman AB, Stoll AL. Omega-3 fatty acids, homocysteine, and the increased risk of cardiovascular mortality in major depressive disorder. Harv Rev Psychiatry 2001;9:280293.
  • 100
    Assies J, Lok A, Bockting CL et al. Fatty acids and homocysteine levels in patients with recurrent depression: an explorative pilot study. Prostaglandins Leukot Essent Fatty Acids 2004;70:349356.
  • 101
    Kemperman RFJ, Veurink M, van der Wal T et al. Low essential fatty acid and B-vitamin status in a subgroup of patients with schizophrenia and its response to dietary supplementation. Prostaglandins Leukot Essent Fatty Acids 2006;74:7585.
  • 102
    Mocking RJT, Assies J, Bot M, Jansen EHJM, Schene AH, Pouwer F. Biological effects of add-on eicosapentaenoic acid supplementation in diabetes mellitus and co-morbid depression: a randomized controlled trial. PLoS ONE 2012;7:e49431.
  • 103
    Kwak SM, Myung SK, Lee YJ, Seo HG, Korean Meta-Analysis Study Group. Efficacy of omega-3 fatty acid supplements (eicosapentaenoic acid and docosahexaenoic acid) in the secondary prevention of cardiovascular disease: a meta-analysis of randomized, double-blind, placebo-controlled trials. Arch Intern Med 2012;172:686694.
  • 104
    Rizos EC, Ntzani EE, Bika E, Kostapanos MS, Elisaf MS. Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis. JAMA 2012;308:10241033.
  • 105
    Roncaglioni MC, Tombesi M, Avanzini F et al. n-3 fatty acids in patients with multiple cardiovascular risk factors. N Engl J Med 2013;368:18001808.
  • 106
    Bloch MH, Hannestad J. Omega-3 fatty acids for the treatment of depression: systematic review and meta-analysis. Mol Psychiatry 2012;17:12721282.
  • 107
    Joy CB, Mumby-Croft R, Joy LA. Polyunsaturated fatty acid supplementation for schizophrenia. Cochrane Database Syst Rev 2006;19:CD001257.
  • 108
    Clarke R, Halsey J, Lewington S et al. Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific mortality: meta-analysis of 8 randomized trials involving 37 485 individuals. Arch Intern Med 2010;170:16221631.
  • 109
    Marti-Carvajal AJ, Sola I, Lathyris D, Karakitsu DE, Simancas-Racines D. Homocysteine-lowering interventions for preventing cardiovascular events. Cochrane Database Syst Rev 2013;1:CD006110.
  • 110
    Martins JG, Bentsen H, Puri BK. Eicosapentaenoic acid appears to be the key omega-3 fatty acid component associated with efficacy in major depressive disorder: a critique of Bloch and Hannestad and updated meta-analysis. Mol Psychiatry 2012;17:11441149.
  • 111
    McNamara RK, Hahn CG, Jandacek R et al. Selective deficits in the omega-3 fatty acid docosahexaenoic acid in the postmortem orbitofrontal cortex of patients with major depressive disorder. Biol Psychiatry 2007;62:1724.
  • 112
    Sartore G, Lapolla A, Reitano R et al. Desaturase activities and metabolic control in type 2 diabetes. Prostaglandins Leukot Essent Fatty Acids 2008;79:5558.
  • 113
    Elizondo A, Araya J, Rodrigo R et al. Effects of weight loss on liver and erythrocyte polyunsaturated fatty acid pattern and oxidative stress status in obese patients with non-alcoholic fatty liver disease. Biol Res 2008;41:5968.
  • 114
    Bell LN, Temm CJ, Saxena R et al. Bariatric surgery-induced weight loss reduces hepatic lipid peroxidation levels and affects hepatic cytochrome P-450 protein content. Ann Surg 2010;251:10411048.
  • 115
    Haugaard SB, Madsbad S, Hoy CE, Vaag A. Dietary intervention increases n-3 long-chain polyunsaturated fatty acids in skeletal muscle membrane phospholipids of obese subjects. Implications for insulin sensitivity. Clin Endocrinol (Oxf) 2006;64:169178.
  • 116
    Puca AA, Andrew P, Novelli V et al. Fatty acid profile of erythrocyte membranes as possible biomarker of longevity. Rejuvenation Res 2008;11:6372.
  • 117
    Tsalouhidou S, Argyrou C, Theofilidis G et al. Mitochondrial phospholipids of rat skeletal muscle are less polyunsaturated than whole tissue phospholipids: implications for protection against oxidative stress. J Anim Sci 2006;84:28182825.
  • 118
    Higdon A, Diers AR, Oh JY, Landar A, Darley-Usmar VM. Cell signalling by reactive lipid species: new concepts and molecular mechanisms. Biochem J 2012;442:453464.
  • 119
    Czobor P, Volavka J, Sheitman B et al. Antipsychotic-induced weight gain and therapeutic response: a differential association. J Clin Psychopharmacol 2002;22:244251.
  • 120
    Oruch R, Lund A, Pryme IF, Holmsen H. An intercalation mechanism as a mode of action exerted by psychotropic drugs: results of altered phospholipid substrate availabilities in membranes? J Chem Biol 2010;3:6788.
  • 121
    Hroudova J, Fidar Z. In vitro inhibition of mitochondrial respiratory rate by antidepressants. Toxicol Lett 2012;213:345352.
  • 122
    Bousquet M, Calon F, Cicchetti F. Impact of omega-3 fatty acids in Parkinson's disease. Ageing Res Rev 2011;10:453463.
  • 123
    Lin PY, Chiu CC, Huang SY, Su KP. A meta-analytic review of polyunsaturated fatty acid compositions in dementia. J Clin Psychiatry 2012;73:12451254.
  • 124
    Sequeira A, Martin MV, Rollins B et al. Mitochondrial mutations and polymorphisms in psychiatric disorders. Front Genet 2012;3:103.
  • 125
    Rollins B, Martin MV, Sequeira PA et al. Mitochondrial variants in schizophrenia, bipolar disorder, and major depressive disorder. PLoS ONE 2009;4:e4913.
  • 126
    Rezin GT, Amboni G, Zugno AI, Quevedo J, Streck EL. Mitochondrial dysfunction and psychiatric disorders. Neurochem Res 2009;34:10211029.
  • 127
    Shao L, Martin MV, Watson SJ et al. Mitochondrial involvement in psychiatric disorders. Ann Med 2008;40:281295.
  • 128
    Halliwell B. Oxidative stress and neurodegeneration: where are we now? J Neurochem 2006;97:16341658.
  • 129
    Halliwell B. The antioxidant paradox. Lancet 2000;355:11791180.
  • 130
    Naviaux RK. Oxidative shielding or oxidative stress? J Pharmacol Exp Ther 2012;342:608618.
  • 131
    Berk M, Copolov D, Dean O et al. N-acetyl cysteine as a glutathione precursor for schizophrenia–a double-blind, randomized, placebo-controlled trial. Biol Psychiatry 2008;64:361368.
  • 132
    Berk M, Malhi GS, Gray LJ, Dean OM. The promise of N-acetylcysteine in neuropsychiatry. Trends Pharmacol Sci 2013;34:167177.
  • 133
    Hsiao FH, Jow GM, Lai YM et al. The long-term effects of psychotherapy added to pharmacotherapy on morning to evening diurnal cortisol patterns in outpatients with major depression. Psychother Psychosom 2011;80:166172.
  • 134
    Lok A, Mocking RJT, Ruhe HG et al. Longitudinal hypothalamic-pituitary-adrenal axis trait and state effects in recurrent depression. Psychoneuroendocrinology 2012;37:892902.
  • 135
    Gulliksson M, Burell G, Vessby B, Lundin L, Toss H, Svardsudd K. Randomized controlled trial of cognitive behavioral therapy vs standard treatment to prevent recurrent cardiovascular events in patients with coronary heart disease: secondary Prevention in Uppsala Primary Health Care project (SUPRIM). Arch Intern Med 2011;171:134140.
  • 136
    Swerdlow RH. Treating neurodegeneration by modifying mitochondria: potential solutions to a “complex” problem. Antioxid Redox Signal 2007;9:15911603.
  • 137
    Roffman JL, Lamberti JS, Achtyes E et al. Randomized multicenter investigation of folate plus vitamin B12 supplementation in schizophrenia. JAMA Psychiatry 2013;70:481489.
  • 138
    Mocking RJ, Lok A, Assies J et al. Ala54Thr fatty acid-binding protein 2 (FABP2) polymorphism in recurrent depression: associations with fatty acid concentrations and waist circumference. PLoS ONE 2013;8:e82980.
  • 139
    Lu Y, Vaarhorst A, Merry AH et al. Markers of endogenous desaturase activity and risk of coronary heart disease in the CAREMA cohort study. PLoS ONE 2012;7:e41681.
  • 140
    Hegarty BD, Parker GB. Marine omega-3 fatty acids and mood disorders – linking the sea and the soul. Acta Psychiatr Scand 2011;124:4251.
  • 141
    Bentsen H, Solberg DK, Refsum H et al. Bimodal distribution of polyunsaturated fatty acids in schizophrenia suggests two endophenotypes of the disorder. Biol Psychiatry 2011;70:97105.
  • 142
    Mocking RJT, Assies J, Koeter MWJ, Ruhe HG, Lok A, Schene AH. Bimodal distribution of fatty acids in recurrent major depressive disorder. Biol Psychiatry 2012;71:e3e5.
  • 143
    Amminger GP, Schafer MR, Papageorgiou K et al. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch Gen Psychiatry 2010;67:146154.
  • 144
    Horwitz RI, Cullen MR, Abell J, Christian JB. Medicine. (De)personalized medicine. Science 2013;339:11551156.
  • 145
    Raison CL, Miller AH. Is depression an inflammatory disorder? Curr Psychiatry Rep 2011;13:467475.
  • 146
    Raison CL, Miller AH. The evolutionary significance of depression in Pathogen Host Defense (PATHOS-D). Mol Psychiatry 2013;18:1537.
  • 147
    Terlecky SR, Terlecky LJ, Giordano CR. Peroxisomes, oxidative stress, and inflammation. World J Biol Chem 2012;3:9397.
  • 148
    Raison CL, Rutherford RE, Woolwine BJ et al. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry 2013;70:3141.
  • 149
    Juel HB, Faber C, Svendsen SG, Vallejo AN, Nissen MH. Inflammatory cytokines protect retinal pigment epithelial cells from oxidative stress-induced death. PLoS ONE 2013;8:e64619.
  • 150
    Serini S, Fasano E, Piccioni E, Cittadini ARM, Calviello G. Dietary n-3 polyunsaturated fatty acids and the paradox of their health benefits and potential harmful effects. Chem Res Toxicol 2011;24:20932105.
  • 151
    Assies J, Mocking RJT, Pouwer F. Letter to the Editor. JAMA 2011;305:360361.
  • 152
    Makrides M, Gibson RA, McPhee AJ, Yelland L, Quinlivan J, Ryan P. Effect of DHA supplementation during pregnancy on maternal depression and neurodevelopment of young children: a randomized controlled trial. JAMA 2010;304:16751683.
  • 153
    Guallar E, Stranges S, Mulrow C, Appel LJ, Miller IR III. Enough is enough: stop wasting money on vitamin and mineral supplements. Ann Intern Med 2013;159:850851.
  • 154
    Daumit GL, Dickerson FB, Wang NY et al. A behavioral weight-loss intervention in persons with serious mental illness. N Engl J Med 2013;368:15941602.
  • 155
    Scheewe TW, Backx FJG, Takken T et al. Exercise therapy improves mental and physical health in schizophrenia: a randomised controlled trial. Acta Psychiatr Scand 2013;127:464473.
  • 156
    Sturm J, Plöderl M, Fartacek C et al. Physical exercise through mountain hiking in high-risk suicide patients. A randomized crossover trial. Acta Psychiatr Scand 2012;126:467475.
  • 157
    Mitchell AJ, Hardy SA. Screening for metabolic risk among patients with severe mental illness and diabetes: a national comparison. Psychiatr Serv 2013;64:10601063.
  • 158
    Rethink Mental Illness. Lethal Discrimination. 2013.